- Home
- ACET vs SST Comparison
ACET vs SST Comparison
Compare ACET & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | SST |
|---|---|---|
| Founded | 1947 | 2013 |
| Country | United States | United States |
| Employees | N/A | 300 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 27.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | SST |
|---|---|---|
| Price | $7.18 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $56.00 | $10.00 |
| AVG Volume (30 Days) | ★ 117.2K | 16.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.29 |
| 52 Week High | $9.05 | $11.30 |
Technical Indicators
Market Signals| Indicator | ACET | SST |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 19.26 |
| Support Level | $6.54 | $0.34 |
| Resistance Level | $8.46 | $4.61 |
| Average True Range (ATR) | 0.46 | 0.32 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 37.24 | 12.96 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.